SG11201908512YA - Somatostatin modulators and uses thereof - Google Patents
Somatostatin modulators and uses thereofInfo
- Publication number
- SG11201908512YA SG11201908512YA SG11201908512YA SG11201908512YA SG 11201908512Y A SG11201908512Y A SG 11201908512YA SG 11201908512Y A SG11201908512Y A SG 11201908512YA SG 11201908512Y A SG11201908512Y A SG 11201908512YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- cornerstone
- court
- suite
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title abstract 4
- 108010056088 Somatostatin Proteins 0.000 title abstract 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 4
- 229960000553 somatostatin Drugs 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472480P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022665 WO2018170284A1 (en) | 2017-03-16 | 2018-03-15 | Somatostatin modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908512YA true SG11201908512YA (en) | 2019-10-30 |
Family
ID=63523267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908512Y SG11201908512YA (en) | 2017-03-16 | 2018-03-15 | Somatostatin modulators and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11072598B2 (https=) |
| EP (1) | EP3596062A4 (https=) |
| JP (1) | JP7106564B2 (https=) |
| KR (1) | KR20190121404A (https=) |
| CN (1) | CN110650951B (https=) |
| AU (1) | AU2018234806A1 (https=) |
| BR (1) | BR112019019168A2 (https=) |
| CA (1) | CA3056131A1 (https=) |
| EA (1) | EA201992083A1 (https=) |
| IL (1) | IL269241B (https=) |
| MX (1) | MX2019010949A (https=) |
| NZ (1) | NZ757081A (https=) |
| SG (1) | SG11201908512YA (https=) |
| TW (1) | TW201840550A (https=) |
| UA (1) | UA127346C2 (https=) |
| WO (1) | WO2018170284A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596062A4 (en) | 2017-03-16 | 2020-08-26 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND THEIR USES |
| MA51840A (fr) | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
| WO2019240246A1 (ja) * | 2018-06-15 | 2019-12-19 | 小野薬品工業株式会社 | ピペリジノール誘導体の新規な塩および新規結晶形 |
| SMT202500155T1 (it) | 2018-09-18 | 2025-05-12 | Crinetics Pharmaceuticals Inc | Modulatori della somatostatina e loro usi |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| WO2021076448A1 (en) * | 2019-10-14 | 2021-04-22 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators for treating pituitary adenomas |
| US12509444B2 (en) * | 2019-12-06 | 2025-12-30 | Plexxikon Inc. | Compounds and methods for CD73 modulation and indications therefor |
| AR121682A1 (es) | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| JP2024506715A (ja) | 2021-02-17 | 2024-02-14 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターの結晶形態 |
| CN117377495A (zh) * | 2021-06-09 | 2024-01-09 | 克林提克斯医药股份有限公司 | 非肽靶向治疗剂及其用途 |
| CN114591326B (zh) * | 2022-02-28 | 2024-02-27 | 上海筛杰生物医药有限公司 | Cct-251921的中间体及其制备方法 |
| IL320483A (en) * | 2022-10-28 | 2025-06-01 | Basecamp Bio Inc | Somatostatin receptor 2 agonists and uses thereof |
| TW202440164A (zh) * | 2022-12-13 | 2024-10-16 | 美商克林提克斯醫藥股份有限公司 | 生長抑素亞型-2受體（sst2r）靶向治療劑及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127343A (en) | 1996-05-14 | 2000-10-03 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
| FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| US20060281764A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| AU2007309708A1 (en) | 2006-03-13 | 2008-05-02 | Merck Sharp & Dohme Corp. | Somatostatin agonists |
| WO2008019967A2 (en) | 2006-08-15 | 2008-02-21 | F. Hoffmann-La Roche Ag | Phenyl, pyridine and quinoline derivatives |
| WO2009051705A1 (en) | 2007-10-18 | 2009-04-23 | Merck & Co., Inc. | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| JP2011526294A (ja) | 2008-06-25 | 2011-10-06 | エンビボ ファーマシューティカルズ インコーポレイテッド | ホスホジエステラーゼ１０阻害剤としての二置換フェニル化合物 |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
| AU2011256444B2 (en) | 2010-05-18 | 2014-07-10 | Merck Sharp & Dohme Corp. | Spiro isoxazoline compounds as SSTR5 antagonists |
| GB201008290D0 (en) | 2010-05-18 | 2010-06-30 | Syngenta Ltd | Chemical compounds |
| WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| US9643951B2 (en) | 2013-09-30 | 2017-05-09 | Ono Pharmaceutical Co., Ltd. | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
| ES2675504T3 (es) | 2013-10-02 | 2018-07-11 | Kuraray Co., Ltd. | Composición de resina, lámina de múltiples capas, material de envasado y recipiente |
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| AU2018219644A1 (en) | 2017-02-08 | 2019-08-29 | Ono Pharmaceutical Co., Ltd. | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
| EP3596062A4 (en) | 2017-03-16 | 2020-08-26 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND THEIR USES |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| MA51840A (fr) | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
| SMT202500155T1 (it) | 2018-09-18 | 2025-05-12 | Crinetics Pharmaceuticals Inc | Modulatori della somatostatina e loro usi |
-
2018
- 2018-03-15 EP EP18767082.3A patent/EP3596062A4/en active Pending
- 2018-03-15 NZ NZ757081A patent/NZ757081A/en unknown
- 2018-03-15 KR KR1020197030515A patent/KR20190121404A/ko not_active Withdrawn
- 2018-03-15 IL IL269241A patent/IL269241B/en unknown
- 2018-03-15 SG SG11201908512Y patent/SG11201908512YA/en unknown
- 2018-03-15 UA UAA201910112A patent/UA127346C2/uk unknown
- 2018-03-15 BR BR112019019168A patent/BR112019019168A2/pt not_active Application Discontinuation
- 2018-03-15 MX MX2019010949A patent/MX2019010949A/es unknown
- 2018-03-15 WO PCT/US2018/022665 patent/WO2018170284A1/en not_active Ceased
- 2018-03-15 EA EA201992083A patent/EA201992083A1/ru unknown
- 2018-03-15 CA CA3056131A patent/CA3056131A1/en not_active Abandoned
- 2018-03-15 AU AU2018234806A patent/AU2018234806A1/en not_active Abandoned
- 2018-03-15 CN CN201880033113.8A patent/CN110650951B/zh active Active
- 2018-03-15 JP JP2019548905A patent/JP7106564B2/ja active Active
- 2018-03-16 TW TW107109163A patent/TW201840550A/zh unknown
-
2019
- 2019-09-16 US US16/572,453 patent/US11072598B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3056131A1 (en) | 2018-09-20 |
| MX2019010949A (es) | 2019-10-24 |
| UA127346C2 (uk) | 2023-07-26 |
| CN110650951A (zh) | 2020-01-03 |
| EP3596062A1 (en) | 2020-01-22 |
| JP2020511452A (ja) | 2020-04-16 |
| BR112019019168A2 (pt) | 2020-04-14 |
| IL269241B (en) | 2022-09-01 |
| TW201840550A (zh) | 2018-11-16 |
| CN110650951B (zh) | 2023-02-24 |
| US11072598B2 (en) | 2021-07-27 |
| EP3596062A4 (en) | 2020-08-26 |
| IL269241A (en) | 2019-11-28 |
| KR20190121404A (ko) | 2019-10-25 |
| AU2018234806A1 (en) | 2019-10-03 |
| US20200010453A1 (en) | 2020-01-09 |
| NZ757081A (en) | 2023-03-31 |
| EA201992083A1 (ru) | 2020-03-18 |
| JP7106564B2 (ja) | 2022-07-26 |
| WO2018170284A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
| SG11201809627QA (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201908159QA (en) | Dual magl and faah inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |